Morgan Stanley Aerovate Therapeutics, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 786,543 shares of AVTE stock, worth $1.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

786,543

Previous 333,968 135.51%

Holding current value

$1.89 Million

Previous $697,000 199.0%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.99 - $2.79 $900,624 - $1.26 Million	452,575 Added 135.51%	786,543 $2.08 Million
Q3 2024 Nov 14, 2024	BUY	$1.61 - $2.09 $454,337 - $589,791	282,197 Added 545.09%	333,968 $697,000
Q2 2024 Oct 17, 2024	BUY	$1.41 - $30.75 $35,938 - $783,756	25,488 Added 96.98%	51,771 $85,000
Q2 2024 Aug 14, 2024	BUY	$1.41 - $30.75 $35,938 - $783,756	25,488 Added 96.98%	51,771 $85,000
Q1 2024 Oct 17, 2024	SELL	$17.68 - $29.57 $450,627 - $753,680	-25,488 Reduced 49.23%	26,283 $777,000
Q1 2024 Aug 16, 2024	SELL	$17.68 - $29.57 $155,035 - $259,299	-8,769 Reduced 25.02%	26,283 $777,000
Q1 2024 May 15, 2024	SELL	$17.68 - $29.57 $155,035 - $259,299	-8,769 Reduced 25.02%	26,283 $777,000
Q4 2023 Aug 16, 2024	SELL	$9.58 - $24.25 $160,168 - $405,435	-16,719 Reduced 32.29%	35,052 $793,000
Q4 2023 Feb 13, 2024	BUY	$9.58 - $24.25 $153,270 - $387,975	15,999 Added 83.97%	35,052 $793,000
Q3 2023 Nov 15, 2023	SELL	$12.9 - $18.88 $180,251 - $263,810	-13,973 Reduced 42.31%	19,053 $258,000
Q2 2023 Aug 14, 2023	SELL	$15.63 - $22.01 $186,747 - $262,975	-11,948 Reduced 26.57%	33,026 $566,000
Q1 2023 May 15, 2023	BUY	$19.17 - $27.7 $820,169 - $1.19 Million	42,784 Added 1953.61%	44,974 $907,000
Q4 2022 Feb 14, 2023	SELL	$15.92 - $30.52 $40,978 - $78,558	-2,574 Reduced 54.03%	2,190 $64,000
Q3 2022 Nov 14, 2022	SELL	$14.77 - $25.79 $46,747 - $81,625	-3,165 Reduced 39.92%	4,764 $78,000
Q2 2022 Oct 27, 2022	BUY	$10.8 - $16.91 $3,996 - $6,256	370 Added 4.89%	7,929 $124,000
Q2 2022 Aug 15, 2022	BUY	$10.8 - $16.91 $3,996 - $6,256	370 Added 4.89%	7,929 $124,000
Q1 2022 Oct 27, 2022	SELL	$8.25 - $18.33 $3,052 - $6,782	-370 Reduced 4.67%	7,559 $139,000
Q1 2022 May 13, 2022	SELL	$8.25 - $18.33 $3,234 - $7,185	-392 Reduced 4.93%	7,559 $139,000
Q4 2021 Feb 14, 2022	BUY	$9.14 - $21.54 $47,619 - $112,223	5,210 Added 190.08%	7,951 $94,000
Q3 2021 Nov 15, 2021	BUY	$11.76 - $22.49 $32,234 - $61,645	2,741 New	2,741 $57,000

Others Institutions Holding AVTE

# of Institutions

Shares Held

30.7M

Call Options Held

186K

Put Options Held

269K

View Full List

About Aerovate Therapeutics, Inc.

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $58.7M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

More about AVTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account